Phase 2 and 3 clinical trials recruiting patients with MALT lymphoma
| Study type . | Clinical trial registration no. . | Trial arms . | Patient population . | Study sponsor . |
|---|---|---|---|---|
| Phase 3 | NCT00877214 | Rituximab maintenance of 2 y vs 4 y | U | Academy |
| Phase 3 | NCT01732913 | Idelalisib vs idelalisib plus rituximab | R/R | Industry |
| Phase 3 | NCT01938001 | Rituximab/lenalidomide vs rituximab | R/R | Industry |
| Phase 3 | NCT01974440 | BR or R-CHOP vs BR plus ibrutinib or R-CHOP plus ibrutinib | R/R | Industry |
| Phase 3 | NCT01996865 | Lenalidomide/rituximab followed by lenalidomide vs lenalidomide/rituximab followed by rituximab | R/R | Industry |
| Phase 2 | NCT00923663 | Lenalidomide | R/R | Academy |
| Phase 2 | NCT01514344 | Intralesional rituximab | R/R | Academy |
| Phase 2 | NCT01516606 | Clarithromycin | R/R | Academy |
| Phase 2 | NCT01678404 | 131I-rituximab | R/R | Academy |
| Phase 2 | NCT01808599 | Chlorambucil and subcutaneous rituximab | U | Academy |
| Phase 2 | NCT01820910 | Doxycycline | U | Academy |
| Phase 2 | NCT02086591 | Doxycycline | R/R | Academy |
| Phase 2 | NCT02332980 | Pembrolizumab | R/R | Academy |
| Phase 2 | NCT01995669 | Lenalidomide plus obinutuzumab | R/R | Academy |
| Phase 2 | NCT02433795 | Bendamustine plus rituximab | R/R | Academy |
| Study type . | Clinical trial registration no. . | Trial arms . | Patient population . | Study sponsor . |
|---|---|---|---|---|
| Phase 3 | NCT00877214 | Rituximab maintenance of 2 y vs 4 y | U | Academy |
| Phase 3 | NCT01732913 | Idelalisib vs idelalisib plus rituximab | R/R | Industry |
| Phase 3 | NCT01938001 | Rituximab/lenalidomide vs rituximab | R/R | Industry |
| Phase 3 | NCT01974440 | BR or R-CHOP vs BR plus ibrutinib or R-CHOP plus ibrutinib | R/R | Industry |
| Phase 3 | NCT01996865 | Lenalidomide/rituximab followed by lenalidomide vs lenalidomide/rituximab followed by rituximab | R/R | Industry |
| Phase 2 | NCT00923663 | Lenalidomide | R/R | Academy |
| Phase 2 | NCT01514344 | Intralesional rituximab | R/R | Academy |
| Phase 2 | NCT01516606 | Clarithromycin | R/R | Academy |
| Phase 2 | NCT01678404 | 131I-rituximab | R/R | Academy |
| Phase 2 | NCT01808599 | Chlorambucil and subcutaneous rituximab | U | Academy |
| Phase 2 | NCT01820910 | Doxycycline | U | Academy |
| Phase 2 | NCT02086591 | Doxycycline | R/R | Academy |
| Phase 2 | NCT02332980 | Pembrolizumab | R/R | Academy |
| Phase 2 | NCT01995669 | Lenalidomide plus obinutuzumab | R/R | Academy |
| Phase 2 | NCT02433795 | Bendamustine plus rituximab | R/R | Academy |
Trials have been selected if registered at ClinicalTrials.gov, and marked as recruiting on December 12, 2015. Sorted by study type and clinical trial registration number.
BR, bendamustine, rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristin, prednisone; R/R, relapsed/refractory; U, untreated.